PPD Discovery signs technology agreement with InforMax
Under the terms of the agreement, PPD Discovery will gain broad access from InforMax to its proprietary bioinformatics system to manage and analyze large quantities of genomic data resulting from PPD's functional genomics research program.
PPD Discovery utilizes its proprietary functional genomics platform, the GSX system, to isolate the functional inhibitors of any selectable cellular property. This technology provides a direct approach to identify and validate novel therapeutic targets based on their functional role in a disease pathway and offers a tool for functional genome annotation. PPD Discovery predicts that by incorporating the GenoMax enterprise bioinformatics system, companies will be able to facilitate the management, analysis and mining of expression and gene function data.
"The molecular structure of the GenoMax bioinformatics system integrates well with our functional genomics platform," said Tanya Holzmayer, co-inventor of the GSX System and Vice President of Genomics at PPD Discovery. "Applying this high throughput system of genomic analysis, we expect to further expedite our identification and validation of novel targets."